These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. In vitro and in vivo antineoplastic activity of a new platinum antineoplastic agent, (R)-(-)-1,1-cyclobutanedicarboxylate (2-aminomethylpyrrolidine)-platinum (II) (DWA2114R) on freshly separated human tumor cells and human tumor xenografts transplanted in nude mice--a comparison with cis-diammine-dichloroplatinum (CDDP). Nio Y; Imai S; Shiraishi T; Tsubono M; Morimoto H; Tseng CC; Tobe T Anticancer Res; 1991; 11(2):761-7. PubMed ID: 2064331 [TBL] [Abstract][Full Text] [Related]
9. Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry. Farrell N Met Ions Biol Syst; 1996; 32():603-39. PubMed ID: 8640533 [No Abstract] [Full Text] [Related]
10. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Hirose A; Sato E; Fujii H; Sun B; Nishioka H; Aruoma OI Toxicol Appl Pharmacol; 2007 Jul; 222(2):152-8. PubMed ID: 17555784 [TBL] [Abstract][Full Text] [Related]
11. [Coordinated platinum compounds in experimental and clinical oncology]. Lobanova EA; Kozlova MD; Singin AS; Serebriakov NG Med Radiol (Mosk); 1984 Jun; 29(6):59-63. PubMed ID: 6376996 [No Abstract] [Full Text] [Related]
12. Combination cancer therapy: Presidential address. Frei E Cancer Res; 1972 Dec; 32(12):2593-607. PubMed ID: 4118763 [No Abstract] [Full Text] [Related]
13. [Chronochemotherapy of neoplasms]. Lackowska B Nowotwory; 1990; 40(3):168-75. PubMed ID: 2243817 [TBL] [Abstract][Full Text] [Related]
14. Further studies on the mechanism of action of hydroxyurea. Yarbro JW Cancer Res; 1968 Jun; 28(6):1082-7. PubMed ID: 5658441 [No Abstract] [Full Text] [Related]
15. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice. Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181 [TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacology of pentamethylmelamine and hexamethylmelamine in mice. Morimoto M; Green D; Rahman A; Goldin A; Schein PS Cancer Res; 1980 Aug; 40(8 Pt 1):2762-7. PubMed ID: 6771004 [No Abstract] [Full Text] [Related]
17. [Antitumor activity of mixed cis-complexes of platinum(II) with ammonia and cycloalkylamines]. Konovalova AL; Presnov MA; Chel'tsov PA; Kravchenko AN; Ivanov VB Dokl Akad Nauk SSSR; 1985; 281(1):200-3. PubMed ID: 4039648 [No Abstract] [Full Text] [Related]
18. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000 [TBL] [Abstract][Full Text] [Related]
19. [The role of the mono-oxygenase system in realizing the biological effects of cisplatin]. Chekhun VF; Pel'kis FP; Kulik GI Vopr Onkol; 1991; 37(9-10):954-8. PubMed ID: 1842656 [TBL] [Abstract][Full Text] [Related]